

Date: October 31, 2026

To
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 532041

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Saturday, October 31, 2026 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI(LODR), 2015"]

Pursuant to Regulation 30 and other applicable Regulations of SEBI (LODR), 2015, the Board of Directors of the Company in its meeting held today i.e., on October 31, 2026:

1. Approved the Un-Audited Standalone Financial Results of the company for the 2nd Quarter ended on 30th September 2026 along with the Limited Review Report.
2. Resignation of Company secretary and Compliance Officer

Took note of and accepted the resignation of Mr. Shailendra Vyas, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, tendered vide his resignation letter dated 31st October, 2026, with effect from the closing hours of 31st October, 2026, due to his decision to pursue an alternative career opportunity outside the Organisation.

The details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated November 11, 2024 are enclosed as **Annexure A**, and a copy of the resignation letter is enclosed as **Annexure B**.

The meeting commenced at 01:00 P.M. and concluded at 02:00 P.M.

This is for your information and records.

Thanking You,
For Hindustan Bio Sciences Limited

VENKATA
RAMA MOHAN
RAJU JAMPANA
RAJU JAMPANA
Date: 2026.10.31 14:03:51
+05'30'

J V R Mohan Raju
Managing Director
DIN: 00060800



HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564


HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026 (Rs. In lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (unaudited)	30.09.2025 (unaudited)	31.03.2026 (Audited)
1	Income from Operations	82.21	0.00	-	82.21	32.19	73.71
	(a) Revenue from operations	2.83	0.00	0.86	2.83	2.17	0
	(b) Other Income	85.04	-	0.86	85.04	34.36	73.71
	Total Revenue (1)						
2	Expenses	-	-	-	-	-	-
	(a) cost of material consumed	46.13	0.00	-	46.13	21.19	44.90
	(b) Purchases of Stock -In-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	5.72	5.72	4.96	11.45	9.36	19.35
	(d) Employee Benefit Expenses	0.07	0.00	0.01	0.07	0.06	0.11
	(e) Finance Costs	0.13	0.01	-	0.14	0.15	0.00
	(f) Selling Expenses	-	0.00	0.39	-	0.39	1.99
	(g) Depreciation and amortisation Expenses	1.95	5.56	1.35	7.51	7.67	15.29
	(h) Other Expenses	54.00	11.29	6.71	65.30	38.82	81.64
	Total Expenses(2)	31.04	(11.29)	(5.85)	19.74	(4.45)	(7.93)
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	-	-	-	-	-	-
4	Exceptional Items	31.04	(11.29)	(5.85)	19.74	(4.45)	(7.93)
5	Profit/(Loss) before tax(3 -4)	-	-	-	-	-	-
6	Tax Expenses	-	-	-	-	-	-
	(a) Current Tax	-	-	-	-	-	(0.03)
	(b) previous Taxes	-	0	-	-	-	(7.89)
	(b) Deferred Tax	31.04	(11.29)	(5.85)	19.74	(4.45)	(7.89)
7	Profit /(Loss) for the period from continuing operations(5-6)	-	-	-	-	-	-
8	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	31.04	(11.29)	(5.85)	19.74	(4.45)	(7.89)
11	Profit/(Loss) for the period(7+10)	-	-	-	-	-	-
12	Other Comprehensive Income	-	-	-	-	-	-
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	31.04	(11.29)	(5.85)	19.74	(4.45)	(7.89)
14	Paid up Equity Capital(Face value of Rs. 2/- each)	205.02	205.02	205.02	205.02	205.02	205.02
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	(122.42)
16	Earnings per equity share for continuing operations	0.30	(0.11)	(0.06)	0.19	(0.04)	(0.08)
	(A) Basic	0.30	(0.11)	(0.06)	0.19	(0.04)	(0.08)
	(B) Diluted	-	-	-	-	-	-
17	Earnings per equity share for discontinuing operations	-	-	-	-	-	-
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations	0.30	(0.11)	(0.06)	0.19	(0.04)	(0.08)
	(A) Basic	0.30	(0.11)	(0.06)	0.19	(0.04)	(0.08)
	(B) Diluted	-	-	-	-	-	-

VENKATA
RAMA MOHAN
RAJU
JAMPANA

Digitally signed by
VENKATA RAMA MOHAN
RAJU JAMPANA
Date: 2026.10.31 14:04:30
+05'30'



HINDUSTAN B+D51+B3:E34+B3:E36+D51+B+B3:E36
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161,Fax 40205171
STATEMENT OF ASSETS AND LIABILITIES

		Rs. In lakhs	
		As at	
	PARTICULARS	30.09.2026	31.03.2026
	ASSETS		
1	Non Current Assets		
	(a) Fixed Assets	1.34	1.34
	Tangible Assets	1.02	1.02
	(b) Deferred Tax Asset	238.96	239.97
	(c) Other Financial Assets		
	Total Non Current Assets	241.33	242.33
2	Current Assets	0	0
	(a) Stock in Trade	47.51	5.30
	(b) Trade Receivables	5.36	13.03
	(c) Cash and Cash Equivalents	57.84	58.87
	(d) Other Current Assets	110.71	77.21
	Total Current Assets	352.04	319.54
	TOTAL ASSETS		
	EQUITY AND LIABILITIES		
1	Share Holders Funds	205.02	205.02
	(a) Share Capital	(102.67)	(122.42)
	(b) Reserves and Surplus	102.34	82.60
	Total of Share Holders Funds		
2	Non Current Liabilities	233.77	234.95
	(a) Borrowings	233.77	234.95
	Total Non Current Liabilities		
3	Current Liabilities	0	0
	(a) Borrowings		
	(b)Trade Payables	0	0
	i.Total Outstanding dues of Micro Enterprises & Small Enterprises		
	ii Total Outstanding dues of Creditors other than Micro Enterprises and small enterprises	0	0.00
	Other Current Liabilities	13.80	0.07
	Short Term Provisions	2.14	1.92
	Sub Total -Current Liabilities	15.93	1.99
	TOTAL EQUITY AND LAIBILITIES	352.04	319.54

Notes:


- 1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.10.2026
- 2 Previous Year figures have been regrouped wherever necessary.

Place: Hyderabad
Date : 31.10.2026

for Hindustan Bio Sciences Limited

VENKATA RAMA
MOHAN RAJU
JAMPANA

J.V.R.Mohan Raju
Chairman & Managing Director
DIN:00060800



HINDUSTAN BIO SCIENCES LIMITED

CIN: L26942TG1991PLC013564

Cash Flow Statement for the quarter and half year ended 30th September,2026
(Rs. In Lakhs)

Particulars	30-09-2026	31-03-2026
		Rs.
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) Before Tax	19.74	(7.93)
Adjustments for:		-
Gain on Sale of Assest	-	-
Depreciation	-	1.99
Operating Profit before Working Capital Changes	19.74	(5.93)
Movements in Working Capital		
Increase/(Decrease) in Trade Payables	13.72	0.01
Decrease/(Increase) in Provisions	0.22	0.62
Increase/(Decrease) in Borrowings	-	-
Increase/(Decrease) in Trade Receivables	(42.21)	38.90
Increase/(Decrease) in Inventories	-	-
Decrease/(Increase) in Other financial assets	1.00	(1.00)
Decrease/(Increase) in Other current assets	1.04	(4.47)
Cash generated from operations	(6.49)	28.13
Less: Income Tax Refund/paid	-	-
Net Cash flow from Operating activities	(6.49)	28.13
B CASH FLOW FROM INVESTING ACTIVITIES		
Sale of Fixed Assets	-	41.06
Purchase of Fixed Assets	-	(41.69)
Net Cash used in Investing activities	-	(0.63)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from/ Repaid Long term Borrowings	(1.18)	(15.56)
Interest paid	-	-
Net Cash used in financing activities	(1.18)	(15.56)
Net increase in cash & Cash Equivalents	(7.67)	11.95
Cash and Cash equivalents at the beginning of the year	13.03	1.09
Cash and Cash equivalents at the end of the year	5.36	13.03
The above Cash Flow statement has been prepared using the Indirect Method as set out in Accounting Standard 3 on Cash Flow Statement.		
Place: Hyderabad		
Date : 31.10.2026		
for Hindustan Bio Sciences Limited		
VENKATA RAMA MOHAN RAJU JAMPANA Digitally signed by VENKATA RAMA MOHAN RAJU JAMPANA Date: 2026.10.31 14:05:18 +05'30'		
J.V.R.Mohan Raju Chairman &Managing Director		



VASG & ASSOCIATES
Chartered Accountants

503/A, 5th Floor, Kubera Towers,
Narayanaguda, Hyderabad - 500 029.
Ph : 040-66849660
E-mail : info.hyd@vasgca.com
vasgassociates@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
STANDALONE FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF

M/S HINDUSTAN BIO SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **M/S. HINDUSTAN BIOSCIENCES LIMITED** (the "Company"), for the quarter ended September 30, 2026, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASG ASSOCIATES
Chartered Accountants
Firm Reg No. 006070S



A. Viswanatha Rao

Partner

Membership No. 029597

UDIN: 26029597ATWTEN7522


Place: HYDERABAD

Date: 31.Oct.2026

Annexure A

The Disclosure required under Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S.No	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Resignation
2.	Date of appointment/cessation (as applicable) & term of appointment;	Closing hours of October 31, 2026
3.	Brief profile (in case of appointment);	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable
Information as per sub-para 7C of Para A of Part A of Schedule III of Listing Regulations		
5.	Letter of Resignation along with detailed reason for resignation	Attached as Annexure B



Date: October 31, 2026

To
The Board of Directors,
Hindustan Bio Sciences Limited,
#31, Sagar Society, Road No.2,
Banjara Hills, Hyderabad, India, 500 034.

Sub: Resignation from the post of Company Secretary of the Company


Dear Sir(s),

I hereby tender my resignation from the position of Company Secretary of the Company (Key Managerial Personnel) with effect from closing hours of October 31, 2026, to pursue an alternate career opportunity outside the Organisation.

My time at Hindustan Bio Sciences Limited has been both professionally rewarding and personally fulfilling. I convey my sincere thanks to the Board of Directors and Senior Management of the Company for their support and co-operation extended to me during my tenure as the Company Secretary of the Company.

You are requested to take note of the same and comply with the necessary formalities.

Thanking you,
Yours Sincerely,



Shailendra Vyas

Membership No. A77193